Drug Patents owned by Albireo
1. List of Bylvay drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7132416 | ALBIREO | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(5 months ago) | |
| US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(16 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10487111 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
| US10981952 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
| US9694018 | ALBIREO | IBAT inhibitors for the treatment of liver disease |
Nov, 2031
(8 years from now) | |
| US10011633 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
| US10093697 | ALBIREO | IBAT inhibitors for the treatment of liver diseases |
Nov, 2031
(8 years from now) | |
| US11365182 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2026 |
| Orphan Drug Exclusivity (ODE) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic)
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic